Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506) - Hwang, Inhwan; Kim, Jeong Eun; Jeong, Jae Ho; Ahn, Jin-Hee; Jung, Kyung Hae; Son, Byung Ho; Kim, Hak Hee; Shin, Junyoung; Lee, Hee Jin; Gong, Gyungyub; Kim, Sung-Bae (Breast cancer research and treatment, 2023)
Keywords: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Breast cancer; Breast Neoplasms - pathology; Cancer research; Cancer therapies; Clinical Trial; Cyclophosphamide; Cyclophosphamide - adverse effects; Docetaxel - therapeutic use; Doxorubicin - adverse effects; Female; Fluorouracil - adverse effects; Humans; Medicine; Medicine & Public Health; NCT; NCT02001506; Neoadjuvant Therapy; Neutropenia; Oncology; Quality of Life; Treatment Outcome; Locally advanced breast cancer; Neoadjuvant; AC followed by docetaxel; FEC followed by docetaxel; Operable breast cancer